Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib DDI Study in Recurrent Ovarian Cancer
NCT04718740Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jun 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fluzoparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Hengrui. Primary endpoint: Pharmacokinetics parameters of caffeine, S-warfarin, omeprazole, midazolam, repaglinide, bupropion and hydroxybupropion at Day 22. Started Jun 2021; status: completed.
02
Drugs
fluzoparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04718740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718740.